Search
Ziresovir
go.drugbank.com/drugs/DB15145InvestigationalZiresovir is under investigation in clinical trial NCT03699202 (Anti-RSV Study in Chinese Patients (ASCENT)).
Thyrotropin
go.drugbank.com/drugs/DB15263InvestigationalThyrotropin is under investigation in clinical trial NCT01348191 (Detection of Thyrotrophin Receptor in Human Myometrium).
Troriluzole
go.drugbank.com/drugs/DB15079InvestigationalTroriluzole is under investigation in clinical trial NCT03701399 (Troriluzole in Adult Subjects With Spinocerebellar Ataxia).
Cyamemazine
go.drugbank.com/drugs/DB09000ExperimentalCyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A). … Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety.
Nisoxetine
go.drugbank.com/drugs/DB09186ExperimentalNisoxetine is a selective norepinephrine reuptake inhibitor (SNRI) developed in the 1970s. … It was originally investigated as an antidepressant but has no current clinical applications aside from being a research standard SNRI.
L-cysteic acid
go.drugbank.com/drugs/DB03661ExperimentalIt occurs normally in the outer part of the sheep's fleece, where the wool is exposed to light and weather. … It is an amino acid with a C-terminal sulfonic acid group which has been isolated from human hair oxidized with permanganate.
Desidustat
go.drugbank.com/drugs/DB16135InvestigationalDesidustat is under investigation in clinical trial NCT04012957 (Desidustat in the Treatment of Anemia in CKD).
Sparteine
go.drugbank.com/drugs/DB06727ApprovedWithdrawnIt is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents.
Desoxyribonuclease
go.drugbank.com/drugs/DB09551ApprovedInvestigationalDesoxyribonuclease is a crystalline enzyme that aids in the digestion of the thymus nucleic acid.
Vopratelimab
go.drugbank.com/drugs/DB15378InvestigationalVopratelimab is under investigation in clinical trial NCT02904226 (JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors).